OXSM: A Potential Drug Target for Omega-3 Fatty Acid Synthesis and Other Diseases

Target Name: OXSM

NCBI ID: G54995

OXSM

OXSM: A Potential Drug Target for Omega-3 Fatty Acid Synthesis and Other Diseases

OXSM (3-oxoacyl-[acyl-carrier-protein] synthase, mitochondrial (isoform 1)) is a protein that is expressed in the mitochondria and is involved in the synthesis of a fatty acid called omega-3 fatty acids, which are essential for the normal functioning of the body. OXSM is a key enzyme in the omega-3 fatty acid synthesis pathway and has been identified as a potential drug target or biomarker for several diseases.

The omega-3 fatty acids are a type of polyunsaturated fatty acid (PUFA) that are important for the structure and function of many cell types in the body. They are involved in the regulation of inflammation, energy metabolism, and brain function, among other things. The body produces omega-3 fatty acids naturally, but they are often difficult to obtain from a diet that is adequate in these nutrients. Therefore, supplementing with omega-3 fatty acids is often recommended for individuals who are not able to obtain them through a healthy diet.

OXSM is the enzyme that is responsible for the synthesis of omega-3 fatty acids from the starting material arachidonic acid. Arachidonic acid is a fatty acid that is derived from the breakdown of certain foods, such as meat and eggs. When arachidonic acid is broken down in the body, it is converted into omega-3 fatty acids, which are then transported to different parts of the body where they are needed.

In addition to its role in the synthesis of omega-3 fatty acids, OXSM has also been shown to have other functions in the body. For example, it has been shown to be involved in the regulation of inflammation in the body. In addition, OXSM has been shown to play a role in the development and progression of certain diseases, such as heart disease and cancer.

Due to its involvement in the synthesis of omega-3 fatty acids and its potential functions in the body, OXSM has been identified as a potential drug target or biomarker for several diseases. For example, studies have shown that OXSM may be a useful target for the treatment of heart disease, as it has been shown to be involved in the regulation of cardiovascular function. In addition, OXSM has also been shown to be involved in the development and progression of certain cancers, so it may be a useful biomarker for these diseases.

Furthermore, there is an increasing interest in OXSM as a potential therapeutic target for the treatment of autoimmune diseases. OXSM is involved in the production of pro-inflammatory cytokines, which contribute to the development and progression of autoimmune diseases. Therefore, inhibiting the activity of OXSM may be a promising approach to the treatment of these diseases.

In conclusion, OXSM is a protein that is expressed in the mitochondria and is involved in the synthesis of omega-3 fatty acids. OXSM has been identified as a potential drug target or biomarker for several diseases, including heart disease, cancer, and autoimmune diseases. Further research is needed to fully understand the role of OXSM in the body and its potential as a therapeutic target.

Protein Name: 3-oxoacyl-ACP Synthase, Mitochondrial

Functions: May play a role in the biosynthesis of lipoic acid as well as longer chain fatty acids required for optimal mitochondrial function

The "OXSM Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OXSM comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets